<?xml version='1.0' encoding='utf-8'?>
<document id="28661568"><sentence text="Everolimus-induced nephrotic syndrome precipitated by interaction with voriconazole in a patient with Hodgkin's lymphoma."><entity charOffset="71-83" id="DDI-PubMed.28661568.s1.e0" text="voriconazole" /></sentence><sentence text="Everolimus is a small molecule that inhibits the mammalian target of rapamycin (mTOR) and is used for treatment of various solid tumours and renal transplant rejection prophylaxis"><entity charOffset="0-10" id="DDI-PubMed.28661568.s2.e0" text="Everolimus" /><entity charOffset="69-78" id="DDI-PubMed.28661568.s2.e1" text="rapamycin" /><pair ddi="false" e1="DDI-PubMed.28661568.s2.e0" e2="DDI-PubMed.28661568.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28661568.s2.e0" e2="DDI-PubMed.28661568.s2.e1" /></sentence><sentence text=" Whereas everolimus-induced proteinuria was previously observed in 3%-36% renal transplant recipients, nephrotic syndrome was not reported in cancer patients taking everolimus"><entity charOffset="9-19" id="DDI-PubMed.28661568.s3.e0" text="everolimus" /><entity charOffset="165-175" id="DDI-PubMed.28661568.s3.e1" text="everolimus" /><pair ddi="false" e1="DDI-PubMed.28661568.s3.e0" e2="DDI-PubMed.28661568.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28661568.s3.e0" e2="DDI-PubMed.28661568.s3.e1" /></sentence><sentence text=" However, nephrotic syndrome was reported in patients taking sirolimus"><entity charOffset="61-70" id="DDI-PubMed.28661568.s4.e0" text="sirolimus" /></sentence><sentence text="" /><sentence text="We report the case of a 32-year-old female with relapsed Hodgkin's lymphoma who was on everolimus for 5 years and developed nephrotic syndrome about 2 months after initiation of voriconazole"><entity charOffset="87-97" id="DDI-PubMed.28661568.s6.e0" text="everolimus" /><entity charOffset="178-190" id="DDI-PubMed.28661568.s6.e1" text="voriconazole" /><pair ddi="false" e1="DDI-PubMed.28661568.s6.e0" e2="DDI-PubMed.28661568.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28661568.s6.e0" e2="DDI-PubMed.28661568.s6.e1" /></sentence><sentence text=" She was on 10 mg everolimus once a day and 200 mg voriconazole twice a day orally"><entity charOffset="18-28" id="DDI-PubMed.28661568.s7.e0" text="everolimus" /><entity charOffset="51-63" id="DDI-PubMed.28661568.s7.e1" text="voriconazole" /><pair ddi="false" e1="DDI-PubMed.28661568.s7.e0" e2="DDI-PubMed.28661568.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28661568.s7.e0" e2="DDI-PubMed.28661568.s7.e1" /></sentence><sentence text=" Renal biopsy revealed thrombotic microangiopathic vasculopathy and thin basement membrane nephropathy" /><sentence text=" Discontinuation of everolimus and voriconazole rapidly improved her nephrotic syndrome"><entity charOffset="20-30" id="DDI-PubMed.28661568.s9.e0" text="everolimus" /><entity charOffset="35-47" id="DDI-PubMed.28661568.s9.e1" text="voriconazole" /><pair ddi="false" e1="DDI-PubMed.28661568.s9.e0" e2="DDI-PubMed.28661568.s9.e0" /><pair ddi="false" e1="DDI-PubMed.28661568.s9.e0" e2="DDI-PubMed.28661568.s9.e1" /></sentence><sentence text="" /><sentence text="We provide in-depth analysis of the underlying mechanisms of everolimus-induced nephrotic syndrome and hypothesize that voriconazole likely decreased everolimus metabolism"><entity charOffset="61-71" id="DDI-PubMed.28661568.s11.e0" text="everolimus" /><entity charOffset="120-132" id="DDI-PubMed.28661568.s11.e1" text="voriconazole" /><entity charOffset="150-160" id="DDI-PubMed.28661568.s11.e2" text="everolimus" /><pair ddi="false" e1="DDI-PubMed.28661568.s11.e0" e2="DDI-PubMed.28661568.s11.e0" /><pair ddi="false" e1="DDI-PubMed.28661568.s11.e0" e2="DDI-PubMed.28661568.s11.e1" /><pair ddi="false" e1="DDI-PubMed.28661568.s11.e0" e2="DDI-PubMed.28661568.s11.e2" /><pair ddi="false" e1="DDI-PubMed.28661568.s11.e1" e2="DDI-PubMed.28661568.s11.e1" /><pair ddi="false" e1="DDI-PubMed.28661568.s11.e1" e2="DDI-PubMed.28661568.s11.e2" /></sentence><sentence text=" In the era of targeted therapy for cancer, healthcare providers should be aware of the drug-drug interaction between everolimus (as well as tyrosine kinase inhibitors) and cytochrome P450 CYP3A4 inhibitors (ie voriconazole)"><entity charOffset="118-128" id="DDI-PubMed.28661568.s12.e0" text="everolimus" /><entity charOffset="141-149" id="DDI-PubMed.28661568.s12.e1" text="tyrosine" /><entity charOffset="211-223" id="DDI-PubMed.28661568.s12.e2" text="voriconazole" /><pair ddi="false" e1="DDI-PubMed.28661568.s12.e0" e2="DDI-PubMed.28661568.s12.e0" /><pair ddi="false" e1="DDI-PubMed.28661568.s12.e0" e2="DDI-PubMed.28661568.s12.e1" /><pair ddi="false" e1="DDI-PubMed.28661568.s12.e0" e2="DDI-PubMed.28661568.s12.e2" /><pair ddi="false" e1="DDI-PubMed.28661568.s12.e1" e2="DDI-PubMed.28661568.s12.e1" /><pair ddi="false" e1="DDI-PubMed.28661568.s12.e1" e2="DDI-PubMed.28661568.s12.e2" /></sentence><sentence text="" /></document>